Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 274

1.

Prognostic significance of hyperfibrinogenemia in patients with lower-risk myelodysplastic syndromes.

Ogura S, Yonei S, Tanigawa T, Akimoto M, Sakurai A, Fujita Y, Ito C, Aisa Y, Nakazato T.

Ann Hematol. 2019 Nov 26. doi: 10.1007/s00277-019-03863-z. [Epub ahead of print] No abstract available.

PMID:
31773214
2.

Species differences in ocular pharmacokinetics and pharmacological activities of regorafenib and pazopanib eye-drops among rats, rabbits and monkeys.

Horita S, Watanabe M, Katagiri M, Nakamura H, Haniuda H, Nakazato T, Kagawa Y.

Pharmacol Res Perspect. 2019 Nov 20;7(6):e00545. doi: 10.1002/prp2.545. eCollection 2019 Dec.

3.

Improving attainment of the critical view of safety during laparoscopic cholecystectomy.

Nakazato T, Su B, Novak S, Deal SB, Kuchta K, Ujiki M.

Surg Endosc. 2019 Oct 11. doi: 10.1007/s00464-019-07178-y. [Epub ahead of print]

PMID:
31605213
4.

Successful treatment with ponatinib for central nervous system relapse of Philadelphia chromosome-positive B-cell acute lymphoblastic leukaemia.

Masuda K, Nakazato T, Nishiyama-Fujita Y, Ito C, Ogura S, Mizuno K, Kamiya T, Aisa Y, Mori T.

Intern Med J. 2019 Oct;49(10):1332-1334. doi: 10.1111/imj.14451. No abstract available.

PMID:
31602766
5.

Potential role for second‑generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia harboring additional clonal chromosome abnormalities: A retrospective CML Cooperative Study Group analysis.

Ishikawa M, Iriyama N, Tokuhira M, Takaku T, Sato E, Sugimoto KJ, Nakazato T, Fujita H, Kimura Y, Fujioka I, Komatsu N, Asou N, Kizaki M, Hatta Y, Kawaguchi T.

Oncol Rep. 2019 Dec;42(6):2836-2843. doi: 10.3892/or.2019.7339. Epub 2019 Sep 27.

PMID:
31578586
6.

Rare case of ocular adnexal relapse with mantle cell lymphoma treated with ibrutinib monotherapy.

Nishiyama-Fujita Y, Nakazato T, Ito C, Ogura S, Mizuno K, Kamiya T, Aisa Y, Mori T.

Intern Med J. 2019 Sep;49(9):1187-1189. doi: 10.1111/imj.14432. No abstract available.

PMID:
31507052
7.

A 1-day simulation-based boot camp for incoming general surgery residents improves confidence and technical skills.

Nakazato T, Callahan Z, Kuchta K, Linn JG, Joehl RJ, Ujiki MB.

Surgery. 2019 Oct;166(4):572-579. doi: 10.1016/j.surg.2019.05.051. Epub 2019 Aug 7.

PMID:
31399217
8.

Dual-mode dopamine increases mediated by 5-HT1B and 5-HT2C receptors inhibition, inducing impulsive behavior in trained rats.

Nakazato T.

Exp Brain Res. 2019 Oct;237(10):2573-2584. doi: 10.1007/s00221-019-05611-1. Epub 2019 Jul 27.

9.

Arylsulfatase A, a genetic modifier of Parkinson's disease, is an α-synuclein chaperone.

Lee JS, Kanai K, Suzuki M, Kim WS, Yoo HS, Fu Y, Kim DK, Jung BC, Choi M, Oh KW, Li Y, Nakatani M, Nakazato T, Sekimoto S, Funayama M, Yoshino H, Kubo SI, Nishioka K, Sakai R, Ueyama M, Mochizuki H, Lee HJ, Sardi SP, Halliday GM, Nagai Y, Lee PH, Hattori N, Lee SJ.

Brain. 2019 Sep 1;142(9):2845-2859. doi: 10.1093/brain/awz205.

PMID:
31312839
10.

Soluble and Planar 2,9-Diazaperopyrenes through Reductive Aromatization of Perylene Diimides: Tunable Emission and Aggregation Behaviors.

Nakamura Y, Nakazato T, Kamatsuka T, Shinokubo H, Miyake Y.

Chemistry. 2019 Aug 9;25(45):10571-10574. doi: 10.1002/chem.201902123. Epub 2019 Jul 17.

PMID:
31264749
11.

The prognostic value of geriatric nutritional risk index in patients with follicular lymphoma.

Mizuno K, Nakazato T, Ito C, Fujita Y, Ogura S, Kamiya T, Sakurai A, Aisa Y, Mori T.

Ann Hematol. 2019 Jul;98(7):1777-1779. doi: 10.1007/s00277-019-03703-0. Epub 2019 Apr 30. No abstract available.

PMID:
31041513
12.

384-Channel electrochemical sensor array chips based on hybridization-triggered switching for simultaneous oligonucleotide detection.

Aoki H, Torimura M, Nakazato T.

Biosens Bioelectron. 2019 Jul 1;136:76-83. doi: 10.1016/j.bios.2019.04.047. Epub 2019 Apr 25.

PMID:
31039490
13.

Smoking influences the outcomes of patients receiving tyrosine kinase inhibitors for chronic myeloid leukemia in the chronic phase: A retrospective analysis.

Iriyama N, Tokuhira M, Sato E, Sugimoto KJ, Takaku T, Ishikawa M, Nakazato T, Fujita H, Kimura Y, Fujioka I, Asou N, Komatsu N, Kizaki M, Hatta Y, Kawaguchi T.

Hematol Oncol. 2019 Aug;37(3):323-325. doi: 10.1002/hon.2617. Epub 2019 Apr 26. No abstract available.

PMID:
30950076
14.

Bortezomib-based strategy with autologous stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan Study Group for Cell Therapy and Transplantation (JSCT-MM12).

Sunami K, Matsumoto M, Fuchida SI, Omoto E, Takamatsu H, Adachi Y, Choi I, Fujishima N, Kiguchi T, Miyamoto T, Maeda A, Suzumiya J, Yamamura R, Nagafuji K, Nakazato T, Kuroda Y, Yujiri T, Takamatsu Y, Harada M, Akashi K.

Int J Clin Oncol. 2019 Aug;24(8):966-975. doi: 10.1007/s10147-019-01436-8. Epub 2019 Apr 1.

PMID:
30937622
15.

Comparative analysis of seven types of superoxide dismutases for their ability to respond to oxidative stress in Bombyx mori.

Kobayashi Y, Nojima Y, Sakamoto T, Iwabuchi K, Nakazato T, Bono H, Toyoda A, Fujiyama A, Kanost MR, Tabunoki H.

Sci Rep. 2019 Feb 18;9(1):2170. doi: 10.1038/s41598-018-38384-8.

16.

Impact of metabolic surgery on health-related quality of life and quality of alimentation.

Seki Y, Pantanakul S, Kasama K, Kikkawa E, Nakazato T, Porciuncula JP.

Surg Obes Relat Dis. 2019 Mar;15(3):488-496. doi: 10.1016/j.soard.2018.12.022. Epub 2018 Dec 22.

PMID:
30711445
17.

The prognostic value of circulating myeloblasts in patients with myelodysplastic syndromes treated with azacitidine.

Kamiya T, Nakazato T.

Med Oncol. 2019 Jan 31;36(3):25. doi: 10.1007/s12032-019-1247-3. No abstract available.

PMID:
30706221
18.

Identification of RNA biomarkers for chemical safety screening in neural cells derived from mouse embryonic stem cells using RNA deep sequencing analysis.

Tani H, Matsutani T, Aoki H, Nakamura K, Hamaguchi Y, Nakazato T, Hamada M.

Biochem Biophys Res Commun. 2019 May 14;512(4):641-646. doi: 10.1016/j.bbrc.2018.11.141. Epub 2018 Nov 26.

PMID:
30497775
19.

Midterm Clinical Outcomes of the St Jude Medical Epic Porcine Bioprosthesis in the Mitral Position.

Nakazato T, Hata H, Toda K, Miyagawa S, Yoshikawa Y, Saito S, Domae K, Ueno T, Kuratani T, Sawa Y.

Circ J. 2018 Dec 25;83(1):110-116. doi: 10.1253/circj.CJ-18-0483. Epub 2018 Oct 25.

20.

Comparison of the clinical outcomes of nilotinib and dasatinib therapies in newly diagnosed patients in the chronic phase of chronic myeloid leukemia: a retrospective analysis.

Iriyama N, Sugimoto KJ, Sato E, Takaku T, Tokuhira M, Nakazato T, Ishikawa M, Fujita H, Fujioka I, Kimura Y, Asou N, Kizaki M, Komatsu N, Hatta Y, Kawaguchi T.

Med Oncol. 2018 Sep 7;35(11):142. doi: 10.1007/s12032-018-1203-7.

PMID:
30194496
22.

Very Late Relapse of Acute Promyelocytic Leukemia 17 Years after Continuous Remission.

Sakurai M, Watanuki S, Kato J, Hashida R, Yamane Y, Karigane D, Mitsuhashi T, Murata M, Ueno H, Nakazato T, Okamoto S, Mori T.

Intern Med. 2018 Nov 15;57(22):3299-3302. doi: 10.2169/internalmedicine.0807-18. Epub 2018 Jul 6.

23.

Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database.

Fujioka I, Takaku T, Iriyama N, Tokuhira M, Kimura Y, Sato E, Ishikawa M, Nakazato T, Sugimoto KJ, Fujita H, Asou N, Kizaki M, Hatta Y, Komatsu N, Kawaguchi T.

Ann Hematol. 2018 Nov;97(11):2081-2088. doi: 10.1007/s00277-018-3412-8. Epub 2018 Jun 26.

PMID:
29946911
24.

Incidence and outcome of second malignancies in patients with chronic myeloid leukemia during treatment with tyrosine kinase inhibitors.

Nakazato T, Iriyama N, Tokuhira M, Ishikawa M, Sato E, Takaku T, Sugimoto KJ, Fujita H, Fujioka I, Kimura Y, Aisa Y, Iwanaga E, Asou N, Kizaki M, Hatta Y, Komatsu N, Kawaguchi T.

Med Oncol. 2018 May 30;35(7):99. doi: 10.1007/s12032-018-1159-7.

PMID:
29846829
25.

A rare case of an acquired factor V inhibitor in a patient with myelodysplastic syndrome during azacitidine treatment.

Fujita Y, Nakazato T, Ito C, Masuda K, Osada Y, Aisa Y, Mori T.

Ann Hematol. 2018 Oct;97(10):2009-2010. doi: 10.1007/s00277-018-3348-z. Epub 2018 May 1. No abstract available.

PMID:
29713749
26.

The prognostic value of positron emission tomography/computed tomography in rheumatoid arthritis patients with methotrexate-associated lymphoproliferative disorders.

Takanashi S, Nakazato T, Aisa Y, Ito C, Arakaki H, Osada Y, Hirano M, Mori T.

Ann Hematol. 2018 Sep;97(9):1611-1618. doi: 10.1007/s00277-018-3327-4. Epub 2018 Apr 30.

PMID:
29713747
27.

The reductive aromatization of naphthalene diimide: a versatile platform for 2,7-diazapyrenes.

Nakazato T, Kamatsuka T, Inoue J, Sakurai T, Seki S, Shinokubo H, Miyake Y.

Chem Commun (Camb). 2018 May 17;54(41):5177-5180. doi: 10.1039/c8cc01937a.

PMID:
29637960
28.

Isaacs syndrome: A slow potassium channelopathy caused by autoantibodies?

Nakazato T, Tsuji Y, Kanai K, Noto YI, Hoshino Y, Yamashiro K, Yokoyama K, Nishioka K, Shimo Y, Watanabe O, Mizuno T, Hattori N.

Clin Neurophysiol. 2018 May;129(5):956-958. doi: 10.1016/j.clinph.2018.01.069. Epub 2018 Feb 15. No abstract available.

PMID:
29554577
29.

Construction of a simple evaluation system for the intestinal absorption of an orally administered medicine using Bombyx mori larvae.

Ichino F, Bono H, Nakazato T, Toyoda A, Fujiyama A, Iwabuchi K, Sato R, Tabunoki H.

Drug Discov Ther. 2018;12(1):7-15. doi: 10.5582/ddt.2018.01004.

30.

Brentuximab vedotin is effective for rheumatoid arthritis in a patient with relapsed methotrexate-associated Hodgkin lymphoma.

Nakazato T, Takanashi S, Hirano M, Ito C, Fujita Y, Osada Y, Aisa Y, Mori T.

Ann Hematol. 2018 Aug;97(8):1489-1491. doi: 10.1007/s00277-018-3279-8. Epub 2018 Feb 17. No abstract available.

PMID:
29455236
31.

Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase.

Tokuhira M, Kimura Y, Sugimoto K, Nakazato T, Ishikawa M, Fujioka I, Takaku T, Iriyama N, Sato E, Fujita H, Hatta Y, Komatsu N, Asou N, Kizaki M, Kawaguchi T.

Med Oncol. 2018 Feb 13;35(3):38. doi: 10.1007/s12032-018-1093-8.

PMID:
29442179
32.

A Simple and Robust Method for Determination of Alkylmercury in Seawater and Industrial Wastewater by Phenylation Pretreatment Combined with GC-MS.

Shigeta K, Tao H, Nakagawa K, Kondo T, Nakazato T.

Anal Sci. 2018;34(2):227-233. doi: 10.2116/analsci.34.227.

33.

Effect of Reprimo Down-regulation on Malignant Transformation of Intraductal Papillary Mucinous Neoplasm.

Nakazato T, Suzuki Y, Tanaka R, Abe N, Masaki T, Mori T, Ohkura Y, Sugiyama M.

Pancreas. 2018 Mar;47(3):291-295. doi: 10.1097/MPA.0000000000001002.

PMID:
29401170
34.

An equation to estimate the renal cortex volume in chronic kidney disease patients.

Nakazato T, Ikehira H, Imasawa T.

Clin Exp Nephrol. 2018 Jun;22(3):603-612. doi: 10.1007/s10157-017-1492-8. Epub 2017 Oct 25.

PMID:
29071505
35.

Gene analysis of inherited antithrombin deficiency and functional analysis of abnormal antithrombin protein (N87D).

Kamijima S, Sekiya A, Takata M, Nakano H, Murakami M, Nakazato T, Asakura H, Morishita E.

Int J Hematol. 2018 Apr;107(4):490-494. doi: 10.1007/s12185-017-2352-8. Epub 2017 Oct 25.

PMID:
29071478
36.

Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography with gallium-67 scintigraphy in the initial clinical staging of diffuse large B-cell lymphoma.

Sakurai M, Toyama T, Kikuchi T, Kato J, Shimizu T, Koda Y, Karigane D, Yamane Y, Abe R, Yamazaki R, Nakazato T, Nakahara T, Jinzaki M, Okamoto S, Mori T.

Int J Hematol. 2018 Feb;107(2):194-200. doi: 10.1007/s12185-017-2337-7. Epub 2017 Oct 9.

PMID:
28994017
37.

Treatment of elderly patients with acute myeloid leukemia.

Nakazato T.

Rinsho Ketsueki. 2017;58(10):1905-1912. doi: 10.11406/rinketsu.58.1905. Japanese.

PMID:
28978831
38.

Introduction of second-generation tyrosine kinase inhibitors may reduce the prognostic impact of high-risk patients, according to the European treatment and outcome study (EUTOS) score.

Sato E, Iriyama N, Tokuhira M, Takaku T, Ishikawa M, Nakazato T, Sugimoto KJ, Fujita H, Fujioka I, Asou N, Komatsu N, Kizaki M, Hatta Y, Kawaguchi T.

Leuk Lymphoma. 2018 May;59(5):1105-1112. doi: 10.1080/10428194.2017.1365858. Epub 2017 Aug 25.

PMID:
28838287
39.

Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma.

Maruyama D, Nagai H, Maeda Y, Nakane T, Shimoyama T, Nakazato T, Sakai R, Ishikawa T, Izutsu K, Ueda R, Tobinai K.

Cancer Sci. 2017 Oct;108(10):2061-2068. doi: 10.1111/cas.13340. Epub 2017 Sep 4.

40.

Clinical characteristics of methotrexate-associated lymphoproliferative disorders: relationship between absolute lymphocyte count recovery and spontaneous regression.

Takanashi S, Aisa Y, Ito C, Arakaki H, Osada Y, Amano Y, Hirano M, Nakazato T.

Rheumatol Int. 2017 Oct;37(10):1629-1633. doi: 10.1007/s00296-017-3764-8. Epub 2017 Jul 5.

PMID:
28676912
41.

Effects of calcineurin inhibitors on sodium excretion in recipients of allogeneic hematopoietic stem cell transplantation.

Saburi M, Kohashi S, Kato J, Koda Y, Sakurai M, Toyama T, Kikuchi T, Karigane D, Yuda S, Yamane Y, Hashida R, Abe R, Nakazato T, Hirahashi J, Ogata M, Okamoto S, Mori T.

Int J Hematol. 2017 Sep;106(3):431-435. doi: 10.1007/s12185-017-2253-x. Epub 2017 May 17.

PMID:
28516402
42.

Comparison of R-CVP with R-CHOP for very elderly patients aged 80 or over with diffuse large B cell lymphoma.

Arakaki H, Nakazato T, Osada Y, Ito C, Aisa Y, Mori T.

Ann Hematol. 2017 Jul;96(7):1225-1226. doi: 10.1007/s00277-017-3017-7. Epub 2017 May 15. No abstract available.

PMID:
28508175
43.
44.

Association between a cardiovascular disease risk assessment and the molecular response to tyrosine kinase inhibitors in chronic-phase chronic myeloid leukemia patients.

Osada Y, Arakaki H, Takanashi S, Ito C, Aisa Y, Nakazato T.

Med Oncol. 2017 Apr;34(4):66. doi: 10.1007/s12032-017-0922-5. Epub 2017 Mar 22. No abstract available.

PMID:
28332166
45.

Relation of dietary inorganic arsenic exposure and urinary inorganic arsenic metabolites excretion in Japanese subjects.

Oguri T, Yoshinaga J, Suzuki Y, Tao H, Nakazato T.

J Environ Sci Health B. 2017 Jun 3;52(6):425-429. doi: 10.1080/03601234.2017.1293453. Epub 2017 Mar 8.

PMID:
28272997
46.

Data integration aids understanding of butterfly-host plant networks.

Muto-Fujita A, Takemoto K, Kanaya S, Nakazato T, Tokimatsu T, Matsumoto N, Kono M, Chubachi Y, Ozaki K, Kotera M.

Sci Rep. 2017 Mar 6;7:43368. doi: 10.1038/srep43368.

47.

Importance of detailed distribution of branches in giant coronary aneurysm.

Kagiyama N, Nakazato T, Yoshida K, Sakaguchi T.

Eur J Cardiothorac Surg. 2017 Feb 1;51(2):394. doi: 10.1093/ejcts/ezw309. No abstract available.

PMID:
28186232
48.

Haplotype-based, case-control study of the receptor (calcitonin) activity-modifying protein (RAMP) 1 gene in essential hypertension.

Nakayama T, Nakazato T, Naruse H, Fu Z, Wang Z, Soma M, Hoshino T, Shimodaira M, Aoi N.

J Hum Hypertens. 2017 May;31(5):361-365. doi: 10.1038/jhh.2016.96. Epub 2017 Feb 9.

PMID:
28181496
49.

Incidences and outcomes of therapy-related chronic myeloid leukemia in the era of tyrosine kinase inhibitors: Surveillance of the CML Cooperative Study Group.

Iriyama N, Tokuhira M, Takaku T, Sato E, Ishikawa M, Nakazato T, Sugimoto KJ, Fujita H, Fujioka I, Hatta Y, Kizaki M, Komatsu N, Asou N, Kawaguchi T.

Leuk Res. 2017 Mar;54:55-58. doi: 10.1016/j.leukres.2017.01.003. Epub 2017 Jan 5.

PMID:
28109974
50.

Identification of functional enolase genes of the silkworm Bombyx mori from public databases with a combination of dry and wet bench processes.

Kikuchi A, Nakazato T, Ito K, Nojima Y, Yokoyama T, Iwabuchi K, Bono H, Toyoda A, Fujiyama A, Sato R, Tabunoki H.

BMC Genomics. 2017 Jan 13;18(1):83. doi: 10.1186/s12864-016-3455-y.

Supplemental Content

Loading ...
Support Center